• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • MANUFACTURERS
  • HEADHUNTERS
  • COMPANIES

SPINEMarketGroup

Spine Industry News

  • HOME
  • 2026
  • 2025
  • 2024
  • BROCHURES
  • ARTICLES
  • PRODUCT LIBRARY

Spineart Secures more than CHF20 Million in Convertible Financing Following Completion of BAGUERA®C IDE Studies Enrollment

March 18, 2024 By SPINEMarketGroup

GENEVA, March 18, 2024 /PRNewswire/ — Spineart, a global spine specialist working with surgeons to accelerate the adoption of cutting-edge technologies, has successfully raised a CHF20 million convertible financing. The funding comes on the heels of the completion of enrollment in the two BAGUERA®C IDE studies, underlining Spineart’s commitment to advancing spinal surgery through large scale investments in research and development. Approximately CHF16 million of the funding was contributed by existing shareholders and employees, with the remaining portion sourced from new investors, above the CHF20 million initial target, with the company exercising its over-allotment allocation option.

“We are thrilled to announce the successful closure of our CHF20 million convertible financing round, which underscores the confidence and support of our investors in Spineart’s vision and innovative technologies,” said Jerome Trividic, CEO of Spineart. “The overwhelming participation from existing shareholders and employees, as well as the addition of new investors, is a testament to the potential of our BAGUERA®C cervical disc prosthesis and our commitment to revolutionizing spinal surgery through enabling technologies and robotic navigation.”

The proceeds from the financing round will be used for several strategic initiatives. These include investments in novel enabling technologies, continued follow-up of patients enrolled in the two BAGUERA®C IDE studies, the opening this summer of Spineart’s new R&D and Training Center for Enabling Technologies in Dallas, Texas, and completion of a new 43,000sqft / 4,300 m2 factory currently under construction near Geneva by the end of 2024.

**About the BAGUERA®C IDE studies:**

The BAGUERA®C IDE studies are pivotal in evaluating the safety and efficacy of Spineart’s innovative BAGUERA®C cervical disc prosthesis, designed to address degenerative cervical disc disorders. The completion of enrollment in these studies marks a crucial step forward in bringing this groundbreaking technology to market in the United States, offering hope to patients suffering from cervical spine conditions.

**About Spineart:**

For more information about Spineart and its innovative spine surgery solutions, please visit www.spineart.com.

SOURCE Spineart

Related Posts:

  • Spineart Completes Enrollment in the Baguera®C IDE…
  • Interim Analysis of 2-Level BAGUERA® C IDE Study…
  • Spine treatment firm Zyga raises $10 million

Filed Under: NEWS Tagged With: 2024

Primary Sidebar

PLATINUM SPONSORS

EXALTA 2LOGO-min
GLOBAL biomedica
NORMED newLOGO-min
GENESYS SPINE
SPINEGUARD2025
Dymicron 2
GSMEDICAL2025
spinewaygroup
RUTHLESS SPINE
RUDISHAUER
NGMEDICAL
LfC
ispine
CENTINEL SPINE
TSUNAMI MEDICAL
syntropiq logo
A-SPINE
L&Kmodelo log

POPULAR POST LAST 90 DAYS

  • Is DePuy Back in the Spine Fight? Why DePuy Really…
  • BROCHURES
  • What Globus Medical Really Bought With Higgs Boson Health
  • Globus Medical Announces Acquisition of Higgs Boson…
  • Globus Medical and Synaptive: Why the Rumors Deserve…
  • Highridge Medical CEO Departure: Spine’s…
  • Thinking About a Spine Robot? Your 2026 Guide to the…
  • DePuy Synthes for Sale: Who Could Actually Buy the…
  • Are Pedicle Screw Lawsuits Becoming a…
  • Federal Circuit Backs Globus Medical in Spinal…
  • COMPANIES
  • Strong Surgery, Soft Quarter: ATEC and the Cost of…
  • The Giant Next Door: Is Mindray Spine’s Next…
  • DePuy Synthes Acquires Expanding Innovations™
  • Forty Cervical Discs, One 3% Market: The Fight to…
  • Globus Medical Reports Second Quarter 2026 Results
  • (UPDATED 2025): 6 Artificial Cervical Discs You’ll…
  • CD HORIZON® SOLERA™ System
  • (UPDATED 2026) More Than 100 Options, No Single…
  • Who Is PAULA, and Why Should Every Deformity Surgeon…
  • J&J’s $21B DePuy Synthes Bet Could End in…
  • Orthopedics Is Moving Into Pain. Zimmer and Globus…
  • ProFlex Spine: Can a Nitinol Implant Crack…
  • Johnson & Johnson Explores Potential $20B Sale…
  • SYMPHONY Occipito-Cervico-Thoracic (OCT) System
  • Top Expandable Cages of 2025: Which Lumbar Implants…
  • CarboFix Spine Launches CarboClear® Hybrid MIS…
  • Globus Medical: Stronger in Spine, but Could DePuy…
  • (2025 Update): Market, Leading FDA-Approved Devices,…
  • Orthofix Discontinues M6-C™ and M6-L™ Artificial…
  • LAST 5 VIDEOS PUBLISHED

    1. NovaSpine: DIVA Cervical
    2. Xenix Medical: Riva Modular Fixation System
    3. Spinal Elements: Overwatch® PCF
    4. Mighty Oak: Acorn 3D™
    5. Syntropiq: Lyra

    Footer

    Contact us:

    spinemarketgroup@gmail.com info@thespinemarketgroup.com

    • LinkedIn
    • Twitter
    • YouTube

    PRIVACY POLICY

    • Legal
    • PRODUCT LIBRARY

    Copyright © 2026 · SPINEMarketGroup